HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Feza Nurözler Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Nurözler, F. Articles by Küçük, G. Search for Related Content PubMed PubMed Citation Articles by Nurözler, F. Articles by Küçük, G.

Aprotinin for Patients Exposed to Clopidogrel Before Off-Pump Coronary Bypass

Division of Cardiovascular Surgery Central Hospital Izmir, Turkey

For reprint information contact: Feza Nurözler, MD Tel: 90 533 332 3088 Fax: 90 232 345 3456 Email: fnurozler{at}yahoo.com, Central Hospital, 1644 sok 2/2, Bayrakli, Izmir, Turkey.

To verify whether low-dose aprotinin reduces blood loss and blood product usage in patients with clopidogrel exposure within 5 days before off-pump coronary artery bypass, 51 patients with clopidogrel exposure were randomized in a double-blind fashion to receive low-dose aprotinin (25 patients), or placebo (26 patients). The baseline characteristics and number of distal anastomoses in the patients in each group were comparable. Time between the last dose of clopidogrel and start of the operation was similar in both groups, as was mean left ventricular ejection fraction. Chest tube drainage, blood product usage, and reoperation rate were significantly higher in the placebo group. In patients with unstable angina and recent clopidogrel exposure who are undergoing off-pump coronary artery bypass, intraoperative administration of low-dose aprotinin is recommended to reduce blood loss and transfusion requirements.